Head-to-head evidence
ALN-HSD vs GSK4532990
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: HSD17B13 · full MASH / NASH pipeline
ALN-HSD
Developed by Alnylam Pharmaceuticals and partners
NCT04565717 · Phase 1 · terminated
A randomized, quadruple-blind, placebo-controlled phase 1 study of ALN-HSD that enrolled only 6 participants, with no results posted to the registry. Randomization and blinding are real, but a study this small cannot support any efficacy comparison, so the design ceiling with the result unknown is weak.
Next expected readout: April 2028 · NCT05519475 (registry estimate)
GSK4532990
Developed by GlaxoSmithKline
NCT06104319 · Phase 2 · completed
The trial randomized participants among four GSK4532990 dose groups, but it was open-label, had no placebo or active comparator, and used biomarker expression rather than a clinical or endoscopic outcome as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALN-HSD's landscape · GSK4532990's landscape